financetom
Business
financetom
/
Business
/
Market Chatter: Seven & i Tells Investors Overhaul Could Almost Double Sales
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Seven & i Tells Investors Overhaul Could Almost Double Sales
Nov 2, 2024 9:26 PM

08:37 AM EDT, 10/24/2024 (MT Newswires) -- Seven & i Holdings Co.'s plan to split in two and expand abroad will help the retailer almost double group revenue, Chief Executive Officer Ryuichi Isaka said in an appeal to shareholders as Alimentation Couche-Tard Inc. ( ANCTF ) seeks to buy the Japanese convenience-store operator, Bloomberg reported overnight Wednesday.

Bloomberg said the retailer aims to reach (Yen)30 trillion ($197 billion) in group sales by the 2030 fiscal year, up from (Yen)17.7 trillion in 2023, with a greater contribution from convenience-store operations in markets abroad.

It noted Seven & i laid out plans earlier this month that will effectively split the company: A business focused on 7-Eleven, convenience stores and gasoline stations, and another made up of less profitable retail operations. The retailer's biggest-ever overhaul is designed to boost its value in the face of a buyout proposal from Couche-Tard that values Seven & i at about (Yen)7.1 trillion.

"Investors should expect global growth," Isaka told analysts Thursday during an investor presentation. Executives are set to meet with key investors in the next week to lay out plans to restructure and expand. "There are countries and regions we haven't reached yet, where there's room for our global network to expand further."

For Japan, the goal is to surpass (Yen)6 trillion in annual domestic sales over the same period, Isaka added.

Bloomberg noted Seven & had rebuffed an earlier, lower offer by the Canadian operator of Circle K stores, saying that it undervalued the company, but hasn't yet responded to Couche-Tard's latest proposal to pay $18.19, or (Yen)2,777, per share. Shares in the Japanese company were trading at (Yen)2,249 during morning trading in Tokyo Thursday, below that price.

Earlier this month, Couche-Tard's top management came to Japan but weren't able to enter negotiations with Seven & i. Chairman and founder Alain Bouchard said during an interview in Tokyo that he's confident the Canadian company can address regulatory concerns.

"We have invited them, we have tried to organize a meeting, but it didn't work, but it will eventually," Bouchard said. The Canadian suitor is optimistic it can arrange financing and address any regulation requirements for a deal.

Bloomberg noted this is the third time in two decades Couche-Tard has tried to enter a deal with Seven & i. A deal would complete the biggest-ever takeover of a Japanese company.

(Market Chatter news is derived from conversations with market professionals globally, and/or from other media sources. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Essential Properties Realty Trust Promotes Max Jenkins to COO
Essential Properties Realty Trust Promotes Max Jenkins to COO
Mar 27, 2025
04:53 PM EDT, 03/27/2025 (MT Newswires) -- Essential Properties Realty Trust ( EPRT ) said late Thursday that Max Jenkins has been promoted to chief operating officer. The company also said it promoted AJ Peil and Robert Salisbury to chief investment officer and head of corporate finance and strategy, respectively. ...
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug
Mar 27, 2025
04:46 PM EDT, 03/27/2025 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) said Thursday that the European Medicines Agency has validated its marketing authorization application for paltusotine, an oral treatment for endocrine disorder acromegaly. The marketing authorization application will now undergo review by the Committee for Medicinal Products for Human Use. This submission is supported by 18 clinical trials, including...
Braze Fiscal Q4 Swings to Profit, Revenue Rises; Shares Gain After Hours
Braze Fiscal Q4 Swings to Profit, Revenue Rises; Shares Gain After Hours
Mar 27, 2025
04:53 PM EDT, 03/27/2025 (MT Newswires) -- Braze (BRZE) reported fiscal Q4 non-GAAP earnings Thursday of $0.12 per diluted share, compared with a loss of $0.04 a year earlier. Analysts polled by FactSet expected earnings of $0.05. Revenue in the three months ended Jan. 31 rose to $160.4 million from $131 million a year earlier. Analysts surveyed by FactSet expected...
EXPLAINER-New creditors' battle emerges in Citgo auction reboot
EXPLAINER-New creditors' battle emerges in Citgo auction reboot
Mar 27, 2025
* New bidding round starts after year-long auction ended in shambles * Creditors' dispute over minimum bid to add more delays in 8-year-old case * Bondholders pact released at Gold Reserve ( GDRZF )-consortium's request * Bids by Venezuela-linked creditors turn auction into creditors game By Marianna Parraga HOUSTON, March 27 (Reuters) - A U.S. federal judge trying to move...
Copyright 2023-2025 - www.financetom.com All Rights Reserved